Table 1 Characteristics of participants who had been on ART for more than 6 months at enrolment by Tenofovir Disoproxil Fumarate (TDF) exposure
Characteristics | All participants n (%) | TDF exposure | |
|---|---|---|---|
Non-TDF ART n (%) | TDF ART n (%) | ||
Alla | 953 | 385 (40.4) | 568 (59.6) |
Socio-demographic/economic | |||
Age (years) | |||
18–34 | 89 (9.3) | 45 (11.7) | 44 (7.7) |
35–49 | 578 (60.7) | 222 (57.7) | 356 (62.7) |
50+ | 286 (30.0) | 118 (30.6) | 168 (29.6) |
Sex | |||
Females | 628 (65.9) | 250 (64.9) | 378 (66.5) |
Males | 325 (34.1) | 135 (35.1) | 190 (33.5) |
SES score tertileb | |||
Low | 403 (42.3) | 165 (42.9) | 238 (41.9) |
Middle | 359 (37.7) | 144 (37.4) | 215 (37.9) |
High | 186 (19.5) | 76 (19.7) | 110 (19.4) |
Lifestyle, anthropometric | |||
Tobacco consumption | |||
Never | 791 (83.0) | 305 (79.2) | 486 (85.6) |
Ex-smoker | 93 (9.8) | 39 (10.1) | 54 (9.5) |
Current | 68 (7.1) | 41 (10.6) | 27 (4.8) |
Alcohol consumption | |||
Never | 358 (37.6) | 141 (36.6) | 217 (38.2) |
Ever >1 month | 352 (36.9) | 135 (35.1) | 217 (38.2) |
Within <1 month | 234 (24.6) | 108 (28.1) | 126 (22.2) |
Body Mass Index (kg/m2) | |||
<18.5 | 91 (9.5) | 30 (7.8) | 61 (10.7) |
18.5–24.9 | 591 (62.0) | 263 (68.3) | 328 (57.7) |
25.0-29.9 | 192 (20.1) | 69 (17.9) | 123 (21.7) |
≥30 | 60 (6.3) | 18 (4.7) | 42 (7.4) |
Clinical, disease history, art | |||
Hypertension | |||
Normal | 722 (75.8) | 299 (77.7) | 423 (74.5) |
Hypertensive | 220 (23.1) | 83 (21.6) | 137 (24.1) |
Glucose (mmol/lL)/history | |||
Desirable (≤6.4 mmol/l) | 912 (95.7) | 375 (97.4) | 537 (94.5) |
High (>6.4 mmol/l) | 33 (3.5) | 10 (2.6) | 23 (4.0) |
Renal disease history | |||
No renal disease | 946 (99.3) | 383 (99.5) | 563 (99.1) |
Known renal disease | 6 (0.6) | 2 (0.5) | 4 (0.7) |
ART regimen type/class | |||
First line ART | |||
2NRTIs/NNRTI | 481 (50.5) | 312 (81.0) | 169 (29.8) |
3NRTIs | 237 (24.9) | 41 (10.6) | 196 (34.5) |
Second line ART (with boosted PI) | 235 (24.7) | 32 (8.3) | 203 (35.7) |
Cotrimoxazole use | |||
Yes | 570 (59.8) | 161 (41.8) | 409 (72.0) |
No | 383 (40.2) | 224 (58.2) | 159 (28.0) |
Total duration on ART (years) | |||
0.5 to <5 | 175 (18.4) | 138 (35.8) | 37 (6.5) |
5 to <9 | 124 (13.0) | 79 (20.5) | 45 (7.9) |
9+ | 654 (68.6) | 168 (43.6) | 486 (85.6) |
HIV-1 viral load (copies/ml) | |||
<1000 | 802 (84.2) | 346 (89.9) | 456 (80.3) |
1000–9999 | 48 (5.0) | 13 (3.4) | 35 (6.2) |
10,000+ | 71 (7.5) | 15 (3.9) | 56 (9.9) |
CD4 cell counts (cells/µl) | |||
≤350 | 263 (27.6) | 102 (26.5) | 161 (28.3) |
351–500 | 274 (28.8) | 120 (31.2) | 154 (27.1) |
501+ | 349 (36.6) | 149 (38.7) | 200 (35.2) |